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See Article, pages 78–86HCV associated liver disease continues to be the most common
indication for liver transplantation in the West. Although the
impact of HCV infection varies substantially between recipients,
allograft failure secondary to recurrence of HCV infection is the
most frequent cause of death and graft failure in HCV infected
recipients. Attenuating the impact of HCV on posttransplant
patient and graft survival has been a critical priority for trans-
plant physicians and their patients. In this edition of the Journal
of Hepatology Duclos-Vallée et al., report the results of a multicen-
ter study of 37 liver transplant recipients (male: 92%, age
57 ± 11 years), who were treated with PEG interferon, ribavirin
and boceprevir (n = 18) or telaprevir (n = 19) for recurrence of
HCV infection following liver transplantation. The indication for
therapy was progressive HCV recurrence (ﬁbrosis stage PF2
(83%) or ﬁbrosing cholestatic hepatitis (16%)). Eighteen patients
were treatment-naive, ﬁve were relapsers and 14 were non-
responders to prior dual therapy after LT. The patient population
was, by and large, typical of recipients with post-LT HCV infection
who are considered for boceprevir and telaprevir based antiviral
therapy. The main ﬁnding of the study by Duclos-Vallée et al., is
that a sustained virological response (SVR) at 12 weeks after
treatment discontinuation was observed in 20% and 71% of
patients in the telaprevir (TVR) and boceprevir (BOC) groups,
respectively, for an overall SVR rate of 50%. While a study with
an n of 37 may seem unimportant, to dismiss the results of this
study would be to miss an opportunity to gain insights into the
opportunities and challenges of treating posttransplant HCV
infection. The report by Duclos-Vallée et al., which is thoughtful
in design and presentation, is not without limitations, including
small sample size, lack of randomization and absence of a pro-
spective antiviral treatment protocol. To focus on the shortcom-
ings would, however, be a disservice to the ﬁeld and the
authors. There are important lessons to be had. The ﬁrst and most
obvious lessons are that boceprevir and telaprevir are neither
particularly effective nor safe in this patient population. WhileJournal of Hepatology 20
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Open access under CC BY-NC-ND license.the authors focus on the ‘‘encouraging’’ complete early virological
response rate (cEVR) of 73%, when it comes to treating HCV, par-
ticularly following liver transplantation, SVR is king. The
observed SVR rate of 50% may be viewed as somewhat less
encouraging than the cEVR rate. The beneﬁt of treatment that
may theoretically eventually be reaped by those recipients who
achieved SVR needs to be weighed against the cost of boceprevir
and telaprevir based antiviral therapy. Three patients (8%) died
on treatment. With only 28 (of 37) patients reaching the com-
bined endpoints of end of treatment/death/treatment discontin-
ued, nine patients are still on treatment. Plenty of opportunity
for participants to die and experience non-lethal adverse events
thus remains. The non-lethal adverse events are of particular
interest. Deterioration in renal function was common, with
5 (14%) of the patients who survived antiviral treatment develop-
ing renal failure, with a mean decline in GFR of 3.8 ml/min during
treatment. As renal function is one of the best predictors of long-
term outcomes, the negative impact of antiviral therapy may con-
tinue well beyond the end of antiviral treatment. Add in one third
of patients getting hospitalized for sundry other adverse events
and one third requiring blood transfusions and the net beneﬁt
is not completely obvious. Only half of ﬁve year posttransplant
mortality/graft loss is due to HCV recurrence. Overall ﬁve year
survival rates for recipients with HCV infection are 70% and
the risk of mortality related speciﬁcally to HCV recurrence is
15% by the ﬁfth postoperative year [1]. A 100% SVR could thus
reduce 5 year post-LT mortality by 15%. With an observed mor-
tality rate related to antiviral treatment in the study by Duclos-
Vallée et al., of 8%, the best case net beneﬁt is a 7% reduction in
ﬁve year mortality attributable to antiviral therapy. As two thirds
of those with the most severe recurrence of HCV did not respond
to antiviral therapy in this study, it is entirely plausible that there
will be no net survival beneﬁt to treating liver transplant recipi-
ents with BOC or TVR in the medium term (the likelihood of mor-
tality/graft loss due to HCV is likely to be highest among the FCH/
cirrhosis patients, who had a low SVR rate). The frequency of SAEs
greatly limited the potential efﬁcacy posttransplant antiviral
therapy in the study by Duclos-Vallée et al., with only half of
the 50% of patients who discontinued treatment doing so for
virological nonresponsiveness/breakthrough, the remainder14 vol. 60 j 6–8
Table 1. Empiric recommended dosing strategies of concomitant protease inhibitors and immunosuppressants when both initiating and discontinuing protease
inhibitor therapy. Empiric dose changes should be done in conjunction with therapeutic drug monitoring.
Drug Mechanism Drug exposure 
effect
Empiric dose changes
At boceprevir 
initiation
At boceprevir 
discontinuation
At telaprevir 
initiation
At telaprevir 
discontinuation
Cyclosporine CYP450 3A4 Inhibition ↑ ↓ 50% ↑ 100% ↓ 75% ↑ 100%
Tacrolimus CYP450 3A4 Inhibition ↑ ↓ 75% ↑ 100% ↓ 90% ↑ 100%
Sirolimus CYP450 3A4 Induction ↑ Black box warning for use in liver transplant recipients.  Recom-
mend everolimus if mTOR inhibitor indicated.
Everolimus CYP450 3A4 Inhibition ↑ ↓ 50% ↑ 100% No published 
data.
Likely ↓ 75%
No published 
data.
Likely ↑ 100%
Mycophenolate mofetil No published interaction No change known No empiric dose adjustments necessary
Azathioprine No published interaction No change known No empiric dose adjustments necessary
Prednisone No published interaction No change known No empiric dose adjustments necessary
JOURNAL OF HEPATOLOGYdying or experiencing adverse events severe enough to stop anti-
viral treatment. A third lesson of the study by Duclos-Vallée et al.,
is that full realization of the potential beneﬁt of BOC and TVR
based posttransplant antiviral therapy requires minimisation of
the side effects of these agents and those of peginterferon and
ribavirin. The high frequency of infections and renal insufﬁciency
suggests overexposure to calcineurin inhibitors. This is despite
effective CNI trough level management through dose adjust-
ments in anticipation of in response to the introduction of the
cytochrome P450 inhibitors boceprevir and telaprevir. Renal
insufﬁciency and life threatening infections despite stable CNI
levels is a consistent emerging theme of posttransplant antiviral
therapy. A thorough appreciation of the impact of post-LT antivi-
ral therapy on the pharmacokinetics of immunosuppression
agents is essential to achieving optimal safety and efﬁcacy.
The cytochrome P450 (CYP) enzyme system is responsible for
drug metabolism via oxidation in the liver and intestines allow-
ing drugs to be eliminated into the bile or urine. The CYP 3A4 iso-
enzyme is used by more than 50% of approved medications for
elimination from the body [1]. Protease inhibitors, such as boce-
previr (BOC) and telaprevir (TVR), in addition to being potent
inhibitors of the CYP 3A4 enzyme leading to many potential
drug-drug interactions (DDI), are also (TVR >BOC) inhibitors of
P-gp, the active transport enzyme, p-glycoprotein (P-gp). P-gp
is an efﬂux pump that ultimately inhibits intestinal absorption
of medications from the gastrointestinal tract. Inhibition of
P-gp can increase concentrations of drugs that would typically
be blocked from absorption into the blood stream. Examples of
medications that will be increased during coadministration of
TVR via P-gp inhibition are morphine [2], digoxin [3] and midaz-
olam [3] (Table 1). The onset of CYP 3A4 inhibition is typically
within the ﬁrst couple of days of protease inhibitor therapy.
BOC and TVR exhibit mechanism-based inhibition of CYP 3A4
meaning that the isoenzyme is inhibited for its life until new
CYP 3A4 protein can be synthesized. The corollary is that resolu-
tion of CYP 3A4 inhibition may be delayed after discontinuing
protease inhibitor therapy. Empiric dose adjustments, judicious
monitoring of co-administered drugs, and screening for potential
adverse effects are warranted during and after BOC and TVR ini-
tiation and discontinuation.
Most available data for drug-drug interactions (DDI) with
these protease inhibitors are in healthy volunteers with normalJournal of Hepatology 2hepatic function. As HCV can decrease CYP function, increasing
calcineurin inhibitor concentrations by approximately 30% [4,5],
pharmacokinetic effects in LT recipients with HCV infection
may be more pronounced than those seen in healthy volunteers.
Tacrolimus doses as little as 0.5 mg per week are adequate to
maintain therapeutic concentrations when given with the prote-
ase inhibitor combination of lopinivir/ritonavir [6]. In healthy
volunteers TVR can increase tacrolimus concentrations as much
as 70-fold and cyclosporine concentrations 4.6-fold [7], while
BOC increases tacrolimus concentrations 17-fold and cyclospor-
ine 2.7 fold [8]. Based on the known effects of BOC and TVR,
CNI and mTOR doses should be decreased empirically when start-
ing protease inhibitor therapy and consequently increased when
protease inhibitor therapy is discontinued. Sirolimus, and everol-
imus are also known substrates of CYP 3A4 and P-gp. No pub-
lished data exist describing the DDI between everolimus and
TVR, however everolimus clearance is decreased by 52%, when
administered with BOC [9]. As sirolimus carries a black box warn-
ing for use in liver transplantation [10], it may be wise to avoid
this agent altogether in patients receiving TVR or BOC. Consider-
ation might be given to everolimus use in place of sirolimus if an
mTOR inhibitor is indicated. The shorter half-life of everolimus
may make management of drug-drug interactions easier than
sirolimus.
DDI can be signiﬁcant in transplant recipients as the calcineu-
rin inhibitors, mTOR inhibitors, and a multitude of other medica-
tions are transported by P-gp and/or metabolized by the CYP 3A4
enzyme. It is important to screen concomitantly administered
medications other than the CNIs and mTORs for potential DDI
or contraindications. Common CYP 3A4 substrates include azole
antifungal agents, HMG-Co-A reductase inhibitors (statins),
methadone, and many others. Increasing the frequency of thera-
peutic drug monitoring of immunosuppressants and other con-
comitant medications is imperative when both starting and
stopping protease inhibitors.
Finally, as all CNI trough levels are measured in whole blood,
trough levels will not accurately reﬂect the biologically active
(immunosuppressive and nephrotoxic) free CNI trough levels.
The major portion of whole blood CsA and TAC is sequestered
in erythrocytes, with hematocrit known to be inversely related
to plasma concentrations of CNIs [11]. Due to RBV induced hemo-
lysis a shift of the erythrocyte-bound CsA fraction to plasma will014 vol. 60 j 6–8 7
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occur. Anemia will be exacerbated by peginterferon and BOC
induced bone marrow suppression. In the context of progressive,
ubiquitous and frequently severe anemia relying on whole blood
level monitoring may not be safe. As free CNI level monitoring is
not widely available, consideration should be given to adjusting
target CNI whole blood trough levels downward in the context
of a falling hematocrit.
On being congratulated for his victory over the Romans at
Heraclea, King Pyrrhus, whose army had suffered irrecoverable
casualties, replied that one more such victory would utterly undo
him. The report by Duclos-Vallée et al., should serve to remind us
of the possibly Pyrrhic nature of our battle with posttransplant
HCV infection. We eagerly await the advent of HCV therapies that
are more effective and more easily tolerated than those that
incorporate BOC and TVR. For patients with mild recurrence,
waiting may be more prudent than joining the battle.Conﬂict of interest
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